Literature DB >> 9578523

Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children.

E Trevathan1, C C Murphy, M Yeargin-Allsopp.   

Abstract

PURPOSE: To determine the prevalence and descriptive epidemiology of Lennox-Gastaut Syndrome (LGS) among metropolitan Atlanta children.
METHODS: We conducted a population-based study of LGS as part of the Metropolitan Atlanta Developmental Disabilities Study (MADDS) using a multiple-source surveillance system for epilepsy and developmental disabilities. Children were defined as having LGS if they had onset of multiple seizure types before age 11 years, with at least one seizure type resulting in falls, and an EEG demonstrating slow spike-wave complexes (<2.5 Hz). Mental retardation (MR) was not used as a diagnostic criterion.
RESULTS: The lifetime prevalence of LGS at age 10 years was 0.26/1,000. Ninety-one percent of those with LGS had MR (IQ < or = 70), and 39% had a history of infantile spasms (IS). A comparison of children with LGS and those with multiple seizure types without slow spike-wave complexes demonstrated that those with LGS were more likely to have MR, history of IS, and multiple disabilities (MR, cerebral palsy, blindness, hearing impairment). Seventeen percent of all children in Atlanta with profound MR (IQ < 20) had LGS.
CONCLUSIONS: LGS accounts for only 4% of all childhood epilepsy, yet is a significant contributor to childhood morbidity.

Entities:  

Mesh:

Year:  1997        PMID: 9578523     DOI: 10.1111/j.1528-1157.1997.tb00065.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

Review 1.  Sex and hormonal influences on seizures and epilepsy.

Authors:  Jana Velíšková; Kara A Desantis
Journal:  Horm Behav       Date:  2012-04-04       Impact factor: 3.587

2.  Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents.

Authors:  John Gilchrist; Stacey Dutton; Marcelo Diaz-Bustamante; Annie McPherson; Nicolas Olivares; Jeet Kalia; Andrew Escayg; Frank Bosmans
Journal:  ACS Chem Biol       Date:  2014-03-31       Impact factor: 5.100

Review 3.  Lennox-Gastaut syndrome: a comprehensive review.

Authors:  Ali A Asadi-Pooya
Journal:  Neurol Sci       Date:  2017-11-09       Impact factor: 3.307

Review 4.  Animal models of absence epilepsies: what do they model and do sex and sex hormones matter?

Authors:  Gilles van Luijtelaar; Filiz Yilmaz Onat; Martin J Gallagher
Journal:  Neurobiol Dis       Date:  2014-08-15       Impact factor: 5.996

5.  The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.

Authors:  Agnes Benedict; Lara Verdian; Grant Maclaine
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Cerebellar atrophy in a child with valproate toxicity.

Authors:  Vidya B Ghosh; Seema Kapoor; Anjali Prakash; Sinchana Bhatt
Journal:  Indian J Pediatr       Date:  2011-01-19       Impact factor: 1.967

7.  Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.

Authors:  Jessica Gresham; Lea S Eiland; Allison M Chung
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

Review 8.  Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.

Authors:  Paul L McCormack
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

9.  Anti-seizure medications for Lennox-Gastaut syndrome.

Authors:  Francesco Brigo; Katherine Jones; Christin Eltze; Sara Matricardi
Journal:  Cochrane Database Syst Rev       Date:  2021-04-07

10.  Treatment of Lennox-Gastaut syndrome: overview and recent findings.

Authors:  Kenou van Rijckevorsel
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.